ReviewRSC advances2025
Benzimidazole(s): synthons, bioactive lead structures, total synthesis, and the profiling of major bioactive categories.
Review in RSC advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Discovery, synthesis, and anti-cancer activity of N-CFMolecular diversity · 2026Article
- Integrated In Vitro and In Silico Evaluation of Benzimidazolium Salts: Antioxidant Activity, Anti-MRSA/MSSA Effects, and Antibacterial Gene Expression Analysis.Antibiotics (Basel, Switzerland) · 2026Article
- From Scaffold to Therapy: Benzimidazole Pharmacophore Evolution in Breast Cancer Research.Chemistry & biodiversity · 2026Review
- Periodic acid-promoted methylenation of imidazoheteroarenes: a green approach using ethylene glycol as a C1 source.RSC advances · 2026Article
- Benzimidazole-Quinoline Hybrids: Synthesis and Antimicrobial Properties.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Multifunctional N-substituted 2-pyridylbenzothiazole derivatives: singlet oxygen generation, protein binding, and photoactivated anticancer and antibacterial activities.RSC advances · 2025Article
- Synthesis and Anticancer Potential of New Benzimidazole Theranostic.ChemistryOpen · 2025Article
- Synthesis of benzimidazoles fromRSC advances · 2025Article
- Magnetic nanohybrids of folic acid as green biocatalysts for the synthesis of heterocyclic compounds.Scientific reports · 2025Article
- Benzimidazole-Pyrimidine Hybrids: Synthesis and Medicinal Properties.Pharmaceuticals (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Benzimidazole, a fused bicyclic compound with benzene and pentacyclic 1,3-diazole moeities, has a simple aromatic heterocyclic structure. The moiety has become an indispensable anchor for the development of new pharmacologically active products, and has yielded several therapeutic agents with anticancer, antihypertensive, antimicrobial, antifungal and antiulcer effects. Benzimidazoles, as synthetically feasible and pharmacophoric synthons, have been relentlessly pursued for the preparation of new analogues and derivatives, and they have successfully developed into some of the most sought-after and vital pharmacophores for drug discovery. The use of varied substituents and differing patterns around the benzimidazole nucleus has provided a wide spectrum of biological activities. In addition, the benzimidazole moiety constitutes a building block for the production of several drugs, drug candidates, new chemical entities, and lead molecules. The importance of this nucleus for bioactivity,
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.